No­vavax breaks an­oth­er pledge for its Covid-19 vac­cine. And the US is re­port­ed­ly fret­ting about glob­al goals now

4 years ago
R&D

FDA adds an­oth­er drug OK to cap a record win list for 2021

4 years ago
FDA+

Fol­low­ing in­flux of cash, Pi­ra­mal in­vests in an­oth­er In­di­an CD­MO; US inks deal with man­u­fac­tur­er of rapid Covid-19 ...

4 years ago
Manufacturing

Low-pro­file RNAi play­er lands on HKEX fol­low­ing mod­est $50M IPO

4 years ago
Financing
China

Not every­body is buy­ing it, but every­body is def­i­nite­ly talk­ing about a new Bio­gen buy­out re­port

4 years ago
R&D

A Jeff Aronin start­up qui­et­ly yanks its IPO as the biotech mar­ket ends year on a whim­per

4 years ago
People
Financing

Hit­ting a new record on drug ap­provals, the FDA of­fers a thumbs-up to an­oth­er atopic der­mati­tis con­tender

4 years ago
FDA+

Sutro strikes a $40M Chi­na deal as it looks to push ahead of a crowd­ed pack

4 years ago
Deals
China

Bridge­Bio shares go in­to melt­down mode as their lead PhI­II drug im­plodes at the fin­ish line

4 years ago
R&D

Covid-19 man­u­fac­tur­ing roundup: In­di­an man­u­fac­tur­er waives vac­cine pro­tec­tions for mi­grants; EMA gives go-ahead for ...

4 years ago
Coronavirus
Manufacturing

No­vo Hold­ings to help young Dan­ish com­pa­ny with ef­forts to pro­vide scale to start-ups

4 years ago
Manufacturing

On the heels of Tezspire ap­proval in US, Am­gen will add fill­ing line in Ire­land

4 years ago
Manufacturing

Durect out-li­cens­es anal­gesic Posimir to Irish biotech in $136M deal; Ar­cutis gets 9-fig­ure loan to push for OK for ...

4 years ago
News Briefing

Inno­gen nets $120M to ad­vance Trulic­i­ty, Ozem­pic ri­val; ven­ture in­to man­u­fac­tur­ing

4 years ago
Financing

FDA au­tho­rizes new Mer­ck Covid-19 pill de­spite sci­en­tist­s' con­cerns on its mech­a­nism of ac­tion

4 years ago
FDA+
Coronavirus

Ar­row­head adds newest fa­cil­i­ty to its Mid­west hub in RNAi drug pro­duc­tion push

4 years ago
Manufacturing

Cincin­nati plays host to new cell, vi­ral vec­tor man­u­fac­tur­ing site from Ex­pres­sion Ther­a­peu­tics

4 years ago
Manufacturing

End­points ed­i­tors se­lect the top trends of 2022: M&A looks hot as IPOs wane, it's time to see some hard da­ta on AI ...

4 years ago
Editor's note
Special

It's a year late, but No­var­tis has fi­nal­ly steered in­clisir­an to FDA ap­proval. Will it sell?

4 years ago
Pharma
FDA+

Covid-19 roundup: No­vavax says vac­cine shows 'broad cross-re­ac­tiv­i­ty' against Omi­cron; France can­cels or­der on ...

4 years ago
Coronavirus

No­var­tis taps Roche's neu­ro and rare dis­ease re­search lead to run neu­ro­science re­search

4 years ago
People
R&D

Joan Shen ends the year by say­ing good­bye to I-Mab; CRISPR Ther­a­peu­tics puts coal in R&D chief's stock­ing

4 years ago
Peer Review

FDA au­tho­rizes the first at-home pills from Pfiz­er to treat Covid-19

4 years ago
FDA+
Coronavirus

Months af­ter miss­ing its PDU­FA date, FDA slaps down Takeda's old Shire drug for eosinophilic esophagi­tis

4 years ago
FDA+
First page Previous page 596597598599600601602 Next page Last page
A service from the Financial Times